Aeglea BioTherapeutics (NASDAQ:AGLE) Share Price Passes Below 50-Day Moving Average of $0.57
Aeglea BioTherapeutics (NASDAQ:AGLE) Share Price Passes Below 50-Day Moving Average of $0.57
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE – Get Rating)'s share price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.57 and traded as low as $0.47. Aeglea BioTherapeutics shares last traded at $0.49, with a volume of 81,533 shares traded.
Aeglea BioTherapeutics, Inc.（纳斯达克股票代码：AGLE — Get Rating）的股价在周四的交易中跌破了其50天移动平均线。该股的50天移动平均线为0.57美元，交易价格低至0.47美元。Aeglea BioTherapeutics股票最后一次交易价格为0.49美元，交易量为81,533股。
Wall Street Analysts Forecast Growth
华尔街分析师预测增长
A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company raised shares of Aeglea BioTherapeutics from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $1.50 to $2.00 in a report on Friday, October 28th. StockNews.com assumed coverage on shares of Aeglea BioTherapeutics in a report on Monday, January 9th. They issued a "hold" rating on the stock. Finally, Piper Sandler increased their price target on shares of Aeglea BioTherapeutics to $1.50 in a report on Tuesday, November 1st. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $1.88.
许多股票研究分析师最近发布了有关该股的报告。富国银行在10月28日星期五的一份报告中将Aeglea BioTherapeutics的股票从 “同等权重” 评级上调至 “增持” 评级，并将该股的目标股价从1.50美元上调至2.00美元。StockNews.com在1月9日星期一的一份报告中假设报道了Aeglea BioTherapeutics的股票。他们对该股发布了 “持有” 评级。最后，派珀·桑德勒在11月1日星期二的一份报告中将Aeglea BioTherapeutics股票的目标股价提高至1.50美元。三位投资分析师对该股进行了持有评级，三位对该公司发布了买入评级。根据Marketbeat.com的数据，该股的平均评级为 “适度买入”，平均目标价为1.88美元。
Aeglea BioTherapeutics Stock Up 2.7 %
Aeglea Biotherapeutics股票上涨2.
The business's 50-day simple moving average is $0.57 and its 200 day simple moving average is $0.60. The firm has a market capitalization of $30.32 million, a P/E ratio of -0.43 and a beta of 1.66.
该公司的50天简单移动平均线为0.57美元，其200天简单移动平均线为0.60美元。该公司的市值为3032万美元，市盈率为-0.43，beta值为1.66。
Institutional Inflows and Outflows
机构流入和流出
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Two Sigma Advisers LP grew its holdings in shares of Aeglea BioTherapeutics by 76.9% in the third quarter. Two Sigma Advisers LP now owns 409,900 shares of the biotechnology company's stock worth $216,000 after purchasing an additional 178,200 shares during the last quarter. Ghost Tree Capital LLC grew its holdings in shares of Aeglea BioTherapeutics by 8.1% in the third quarter. Ghost Tree Capital LLC now owns 1,000,000 shares of the biotechnology company's stock worth $526,000 after purchasing an additional 75,000 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Aeglea BioTherapeutics by 5.6% in the second quarter. Goldman Sachs Group Inc. now owns 1,187,293 shares of the biotechnology company's stock worth $600,000 after purchasing an additional 62,504 shares during the last quarter. Nantahala Capital Management LLC grew its holdings in shares of Aeglea BioTherapeutics by 21.1% in the second quarter. Nantahala Capital Management LLC now owns 3,877,311 shares of the biotechnology company's stock worth $1,958,000 after purchasing an additional 676,718 shares during the last quarter. Finally, Bain Capital Life Sciences Investors LLC grew its holdings in shares of Aeglea BioTherapeutics by 87.8% in the second quarter. Bain Capital Life Sciences Investors LLC now owns 5,347,689 shares of the biotechnology company's stock worth $2,701,000 after purchasing an additional 2,500,000 shares during the last quarter. 78.01% of the stock is currently owned by institutional investors.
许多机构投资者和对冲基金最近买入和卖出了该公司的股票。Two Sigma Advisors LP在第三季度将其持有的Aeglea BioTherapeutics股票增加了76.9％。Two Sigma Advisors LP在上个季度又购买了178,200股股票后，现在拥有这家生物技术公司的409,900股股票，价值21.6万美元。Ghost Tree Capital LLC在第三季度将其持有的Aeglea BioTherapeutics股票增加了8.1％。Ghost Tree Capital LLC在上个季度又购买了7.5万股股票后，现在拥有这家生物技术公司的100万股股票，价值52.6万美元。高盛集团公司在第二季度将其持有的Aeglea BioTherapeutics股票增加了5.6％。高盛集团公司在上个季度又购买了62,504股股票后，现在拥有这家生物技术公司的1,187,293股股票，价值60万美元。Nantahala Capital Management LLC在第二季度将其持有的Aeglea BioTherapeutics股票增加了21.1％。Nantahala Capital Management LLC在上个季度又购买了676,718股股票后，现在拥有这家生物技术公司的3,877,311股股票，价值1958,000美元。最后，贝恩资本生命科学投资有限责任公司在第二季度将其持有的Aeglea BioTherapeutics股票增加了87.8％。Bain Capital Life Sciences Investors LLC在上个季度又购买了250万股股票后，现在拥有这家生物技术公司的5,347,689股股票，价值27.01万美元。该股票的78.01％目前由机构投资者持有。
About Aeglea BioTherapeutics
关于 Aeglea Biotherape
(Get Rating)
（获取评分）
Aeglea Biotherapeutics, Inc is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency.
Aeglea Biotherapeutics, Inc是一家临床阶段的生物技术公司，致力于开发下一代人类酶疗法，以此作为罕见疾病和其他高负担疾病的颠覆性解决方案。其产品Pegzilarginase正在进行治疗精氨酸酶1缺乏症的3期关键试验。
See Also
另见
- Get a free copy of the StockNews.com research report on Aeglea BioTherapeutics (AGLE)
- Does Oil Services Firm NOV Have Enough Energy To Maintain Rally?
- Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- The Future Of E-Commerce: Analysis And New Data
- Levi Strauss Is A Good Fit For Income Investors
- 免费获取 StockNews.com 关于 Aeglea BioTherapeutics (AGLE) 的研究报告
- 石油服务公司NOV有足够的能量来维持涨势吗？
- Shopify 清理了带手柄的杯子底座：势头能否持续下去？
- 雪佛龙通过750亿美元的股票回购使股东感到高兴
- 电子商务的未来：分析和新数据
- 李维·施特劳斯非常适合收入投资者
Receive News & Ratings for Aeglea BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Aeglea BioTherapeutics Daily -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Aeglea BioTherapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。